On October 11, 2023, the American Society of Clinical Oncology (ASCO) recommended an update to its treatment guidelines for small cell lung cancer (SCLC). Cosela (trilaciclib) has been recommended as a myeloid supportive agent for individuals with extensive-stage SCLC who [...]